Genexine has been granted a patent for a method to treat cervical tumors caused by HPV infection. The method involves administering a combination of an HPV-specific fusion protein and an immunomodulatory agent. Additionally, a method for treating HPV-induced cancer includes administering an HPV vaccine and a checkpoint inhibitor agent simultaneously for enhanced therapeutic effect. GlobalData’s report on Genexine gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Genexine Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genexine, Peptide pharmacophores was a key innovation area identified from patents. Genexine's grant share as of February 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of hpv-induced cancer using combination of hpv vaccine and checkpoint inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Genexine Inc

A recently granted patent (Publication Number: US11883479B2) outlines a method for treating human papillomavirus (HPV)-induced cancer by administering an HPV vaccine and a checkpoint inhibitor agent to the subject simultaneously. The combination treatment aims to generate a more significant therapeutic effect compared to using either the HPV vaccine or checkpoint inhibitor alone as monotherapy. The HPV vaccine, which may include a specific nucleic acid construct, is administered multiple times at a dose of 0.5-5 mg, while the checkpoint inhibitor, typically a PD-1/PD-L1 inhibitor like pembrolizumab, is given at a dose ranging from 50 mg to 500 mg.

Furthermore, the method specifies the administration route for the HPV vaccine as intramuscular and for the checkpoint inhibitor as intravenous. The treatment regimen involves multiple administrations of both therapies over a common period of at least 13 weeks, with the first doses of each occurring on the same day. The patent emphasizes the application of this method for treating metastatic, recurrent, or advanced cervical cancer caused by HPV, particularly HPV 16 or HPV 18, in subjects who may be PD-L1 positive or negative. The innovative approach of combining these two distinct treatments within a specific timeframe showcases a promising strategy for enhancing the therapeutic outcomes in HPV-induced cancer patients.

To know more about GlobalData’s detailed insights on Genexine, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies